CASI Pharmaceuticals, Inc.
34.80%
8,965,535
1962738
G1933S101
Jan 26, 2026
Jan 29, 2026, 07:21 PM
Reporting Persons (7)
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| WEI-WU HE, Ph.D. | Individual | 34.80% | 8,965,535 | 2,130,550 | 6,834,985 |
| ETP Global Fund III L.P. | Partnership | 19.60% | 5,000,000 | 0 | 5,000,000 |
| EMERGING TECHNOLOGY PARTNERS, LLC | Other | 5.30% | 1,097,341 | 0 | 1,097,341 |
| ETP Global Fund L.P. | Partnership | 3.70% | 753,234 | 0 | 753,234 |
| HUIYING MEMORIAL FOUNDATION | CO | 3.10% | 637,644 | 0 | 637,644 |
| ETP BIOHEALTH III FUND, L.P. | Partnership | 1.50% | 300,000 | 0 | 300,000 |
| HE Family GRAT | Other | 0.50% | 100,000 | 0 | 100,000 |
Disclosure Items (7)
Ordinary Shares
CASI Pharmaceuticals, Inc.
1701-1702, CHINA CENTRAL OFFICE TOWER 1, BEIJING, F4, 100025
Item 2(a)-(f) of the Schedule 13D is hereby amended and supplemented by the following: ETP Global Fund III L.P. is a limited partnership organized under the laws of Delaware and controlled by Dr. Wei-Wu He. The business address of ETP Global Fund III L.P. is 4919 Rebel Ridge Dr, Sugar Land, TX 77878.
As described in Item 4 below, on December 27, 2025, ETP Global Fund III L.P. purchased a convertible note with a principal amount of US$5 million using its working capital pursuant to certain Note Purchase Agreement between ETP Global Fund III L.P. and the Issuer dated December 11, 2025.
See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of Ordinary Shares and percentages of the Ordinary Shares beneficially owned by each Reporting Person. The percentage used in this Schedule 13D is calculated based upon 20,555,873 Ordinary Shares outstanding as of January 28, 2026.
See rows (7) through (10) of the cover pages to this Schedule 13D for the number of Ordinary Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.
See Item 4, Purpose of Transaction.
No person other than the Reporting Persons is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Shares.
Not applicable.
The descriptions of the principal terms of the Proposal under Item 4 are incorporated herein by reference in their entirety. To the best knowledge of the Reporting Persons, except as provided herein and disclosed before, there are no other contracts, arrangements, understandings or relationships (legal or otherwise) between the Reporting Persons and between any of the Reporting Persons and any other person with respect to any securities of the Company, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, divisions of profits or loss, or the giving or withholding of proxies, or a pledge or contingency, the occurrence of which would give another person voting power over the securities of the Company.
Exhibit A Joint Filing Agreement by and among ETP Global Fund LP, Emerging Technology Partners LLC, ETP BioHealth III Fund, LP, HE Family GRAT and Wei-Wu He, Ph.D. dated April 18, 2023. Exhibit B Convertible Note, dated December 27, 2025, issued to ETP Global Fund III L.P.